Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.56 |
| ▸ | GSK3B | P49841 | 8/20 | 0.56 |
| ▸ | SRC | P12931 | 6/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.51 |
| ▸ | GSK3A | P49840 | 3/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 9/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104805 | 0.75 | AURKA (0.50) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL5106907 | 0.73 | EGFR (0.43) | AURKAGSK3BSRCEIF2AK2PDGFRB | |
| SCHEMBL801702 | 0.73 | GSK3B (0.65) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL12430654 | 0.72 | AURKA (1.00) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL3869550 | 0.72 | ITK (0.51) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL9820151 | 0.72 | MEN1 (0.65) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL12430650 | 0.71 | NTRK1 (0.89) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL12510631 | 0.70 | AURKA (0.88) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL21925754 | 0.69 | AURKA (0.47) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL16534531 | 0.69 | ITK (0.60) | AURKAGSK3BSRCAURKBGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | claimed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | claimed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | claimed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | AURKA 196/4885GSK3B 429/4885SRC 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.